A.K. Koutras, I. Starakis, U. Kyriakopoulou, P. Katsaounis, A. Nikolakopoulos and H.P. Kalofonos Pages 1599 - 1612 ( 14 )
Treatment of metastatic colorectal cancer (mCRC) has progressed significantly over the last years, particularly with the introduction of targeted therapies. Two groups of agents targeting either the epidermal growth factor receptor (EGFR) or the vascular endothelial growth factor (VEGF) have been integrated into clinical practice. Currently available agents with established role include the anti-EGFR monoclonal antibodies (mAbs) cetuximab / panitumumab and the anti-VEGF mAb bevacizumab. This review presents an update on the clinical studies evaluating the role of anti-EGFR and anti-VEGF agents in mCRC. Moreover, we provide current data regarding the mechanism of action and pathways mediating resistance to these agents. In addition, we present recent data with respect to biomarkers and we discuss future therapeutic strategies.
Bevacizumab,cetuximab,colorectal cancer,panitumumab,targeted therapy
, , , , , Division of Oncology, Department of Medicine, University Hospital, Patras Medical School, Rion 26504, Greece.